Is Titan Medical a Good Medical Equipment Stock to Add to Your Portfolio?

: TMDI | Titan Medical Inc. News, Ratings, and Charts

TMDI – Toronto-based Titan Medical (TMDI) is a small company in the growing medical robotic equipment space. The company is developing its Enos system—a potentially new standard of care in robotic single access surgery. But should investors scoop up its shares at this stage? Let’s find out.

Based in Toronto, Canada, Titan Medical Inc. (TMDI) is a micro-cap company in the growing medical devices space. It has $182.57 million in market capitalization and is focused on developing computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). According to a report by Market Research Engine, the global medical robotic system market is expected to grow at a CAGR of 14.5% over the next four years. However, TMDI is not yet positioned favorably to capitalize on the industry tailwinds.

TMDI’s stock  has lost 15.4% over the past month to close yesterday’s trading session at $1.70. It is currently trading 51% below its 52-week high of $3.47. 

On December 24, TMDI  regained full compliance with all applicable criteria for continued listing and trading on the Nasdaq Capital Market. However, the company  is still in its initial development stage and has not yet provided a definite timetable for completing the development of its Enos system.

Click here to checkout our Healthcare Sector Report for 2021

So, here’s what we think could shape TMDI’s performance in the near term:

Enos System Not Yet Fully Developed

In 2020, TMDI rebranded its surgical system in development–the SPORT surgical system–to the Enos robotic single access surgical system to better represent its focus. The company is developing the Enos system to become the new standard of care in robotic single access surgery, with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. However, the system is not yet  fully developed and must be submitted for approval to the U.S. Food and Drug Administration (FDA) (and potentially  other regulatory authorities) when it is. . So, it could be some time before TMDI makes the system  commercially available.

Weak Financials

TMDI’s loss for the quarter ended December 31, 2020 was $20.60 million compared to a  $2.40 million gain in the prior-year period. The loss  was due primarily to an increase in non-cash losses on the fair value of $29.80 million in warrants and an increase of $3.4 million in research and development expenses. TMDI’s loss for the year ended December 31, 2020 was  $24.20 million and its loss per share was  $0.36.

Selling Shares to Fund Growth Activities

In February, TDMI closed an offering  of 8,335,000 units of its shares. The offering  generated $23 million in proceeds> The company plans to use   the proceeds to fund the development of robotic surgical technologies and for general working capital. POWR Ratings Indicate Weak Prospects

TMDI has an overall D rating, which equates to Sell in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors with the weighting of each optimized to improve overall performance.

Our proprietary rating system also evaluates each stock based on eight different categories. TMDI has a C grade for Value. This is in sync with its forward EV/Sales of 7.78x, which is 17% higher than the industry average of 6.65x. In terms of forward P/S ratio, its 8.88x is higher than the industry average  7.16x.

It has a C grade for Momentum also. This is consistent with its 15.4% loss over the past month and 9.1% loss over the past three months. The stock also has a F grade for Stability.

TMDI is ranked #139 of 185 stocks in the C-rated Medical – Devices & Equipment industry. Click here to see the additional POWR Ratings for TMDI (Growth, Sentiment, and Quality).

Better than TMDI: Click here to access several other top-rated stocks in the same industry.

Bottom Line

TMDI executed a license agreement with Medtronic plc. (MDT) in June 2020. However, the Enos system is not yet  fully developed. The company is expected to complete human clinical study in 2022. So, its near-term prospects seem uncertain. The company’s financials don’t give a buy signal either. As a result, we think it’s wise to avoid the stock now.

Click here to checkout our Healthcare Sector Report for 2021

 


TMDI shares were trading at $1.67 per share on Thursday morning, down $0.03 (-1.76%). Year-to-date, TMDI has declined -2.34%, versus a 11.32% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
TMDIGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Top 10 Value Stocks

The S&P 500 (SPY) has shown mixed results in the last week, but if you are a value investor, then yesterday was a big day. That’s when we revealed to our readers the fatal flaws of traditional value investing and the solution to this problem—our Top 10 Value Stocks strategy. Read on below to find out more about this 3-step process and its +38.63% annual returns…

:  |  News, Ratings, and Charts

5 Cheap Growth Stocks for Q2 2021

After a brief selloff in Q1 2021, growth stocks are once again in focus. Investors can take advantage of this by investing in growth companies such as Johnson & Johnson (JNJ), Target (TGT), Dell Technologies (DELL), Agilent Technologies (A), and Goldman Sachs (GS) that are trading at low valuations.

:  |  News, Ratings, and Charts

2 Buy-Rated Big Data Stocks to Own for the 5G Revolution

The 5G revolution is expected to drive the growth of cloud computing and data analytics in the coming months as most industries exploit faster execution. As such, we think big-data stocks Teradata (TDC) and Cloudera (CLDR) could witness solid upside in the coming months. Read on.

:  |  News, Ratings, and Charts

Grab These 2 Beaten Down Tech Stocks Before They Rebound

While tech shares soared last year, some stocks saw their shares retreat in 2021. In fact, a number of solid companies have been beaten down over the past few weeks, which provides a great buying opportunity. Read more to learn why Patrick Ryan thinks you should consider F5 Networks (FFIV) and MACOM Technology Solutions Holdings (MTSI).

:  |  News, Ratings, and Charts

2 Buy-Rated Big Data Stocks to Own for the 5G Revolution

The 5G revolution is expected to drive the growth of cloud computing and data analytics in the coming months as most industries exploit faster execution. As such, we think big-data stocks Teradata (TDC) and Cloudera (CLDR) could witness solid upside in the coming months. Read on.

Read More Stories

More Titan Medical Inc. (TMDI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TMDI News